BUSINESS

• Shionogi’s Half-Year Profits Renew Records, but Crestor Generics Weigh on Topline
  October 30, 2018

• Shionogi Chief Confident about 70% Market Share for Xofluza in Japan
  October 30, 2018

• Europe OKs Xtandi for All CRPC Cases
  October 30, 2018

• JCR Initiates Development of Temcell for Epidermolysis Bullosa
  October 30, 2018

• Takeda Mulls Sale of Shire GI Pipeline to Clinch European Clearance
  October 29, 2018

• Fujifilm Signs MOU on Clinical Development of Favipiravir in China with 3 Chinese Partners
  October 29, 2018

• Taiho’s Lonsurf Grabs US Priority Review Status for Gastric Cancer
  October 29, 2018

• Daiichi Sankyo, Merck KGaA, Pfizer to Collaborate for PI of DS-8201, Bavencio, and DDR Combo
  October 29, 2018

• Lemborexant Improves Nighttime Activity in AD Patients with Irregular Sleep-Wake Rhythm Disorder in PII: Eisai
  October 29, 2018

• Eisai, Biogen Tout BAN2401’s Clinical Effect Regardless of APOE4 Mutation
  October 29, 2018

• Shionogi, Osaka Univ. to Collaborate on Medical Data Science for Effective Use of Real-World Data
  October 26, 2018

• Eisai to Offer 3 Rounds of Voluntary Retirement Program, to Cut 100 Jobs in March Next Year
  October 26, 2018

• Xofluza Bags US Approval: Shionogi
  October 26, 2018

• Tecentriq, Hemlibra Get Off with a Bang, Clear 2018 Targets Already: Chugai
  October 25, 2018

• Swiss API Manufacturer Bachem Establishes Japanese Subsidiary
  October 25, 2018

• GSK to Cover Cost of Rubella Testing and Vaccination for Employees
  October 25, 2018

• AVXS-101 Is Game Changer for SMA Treatment: Novartis Neuroscience Chief
  October 24, 2018

• Meiji Seika Pharma Files Safinamide for Parkinson’s Disease in Japan
  October 24, 2018

• Regenerative Medicine Product Market to Reach 225 Billion Yen in 2030: Fuji Keizai
  October 24, 2018

• Parexel CEO Sees Bright Future for Japan CRO Market
  October 23, 2018

ページ

• « 先頭
• ‹ Prev
• …
• 366
• 367
• 368
• 369
• 370
• 371
• 372
• 373
• 374
• …
• Next ›
• 最終 »